All 9 candidates scored 5/7 Graham. Deep analysis adds Dorsey moat, Klarman downside, Schilit quality, insider signal, analyst sentiment, balance sheet, and earnings momentum.
| Rank | Ticker | Sector | Price | Fwd P/E | Net D/EBITDA | Moat | Insider | Analyst | Earnings | Schilit | Conviction |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AIG | Financial Svcs | $75.42 | 8.5x | 0.22x(fin) | Narrow | CFO bought $86 | 8 Buy/0 Sell | 4/4 beats, +43% | 1 flag | HIGH |
| 2 | PHM | Consumer Cyc | $117.29 | 10.4x | 0.10x | Narrow (Del Webb) | Neutral | 13 Buy/1 Sell | 4/4 adj beats | 2 flags | MEDIUM-HIGH |
| 3 | DD | Basic Materials | $45.48 | 17.9x | 1.52x | Narrow-Wide | Neutral | 23 Buy/0 Sell | 8/8 beats | 1 flag | MEDIUM (not cheap) |
| 4 | DHI | Consumer Cyc | $139.69 | 11.3x | 0.66x | Narrow | No buys | 6 Buy/2 Sell | 2/4 beats, -22% | 0 flags | MEDIUM |
| 5 | TROW | Financial Svcs | $90.17 | 9.0x | Net cash | Narrow (eroding) | Neutral | 0 Buy/8 Sell | Flat | 1 flag | MEDIUM (contrarian) |
| 6 | HUM | Healthcare | $177.83 | 19.8x(guide) | 2.29x | Narrow | Dir bought $2.8M | 10 Buy/2 Sell | Q4 -64% miss | 2 flags | HIGH RISK/REWARD |
| 7 | SWKS | Technology | $55.19 | 11.1x | Net cash | Narrow (narrowing) | No buys, sells | 5 Buy/1 Sell | 4/4 beats | 1 flag | LOW (Apple risk) |
| 8 | LEN | Consumer Cyc | $86.49 | 11.2x | 0.71x | Narrow (narrowing) | No buys | 3 Buy/7 Sell | 4/4 misses | 1 flag | LOW |
| 9 | BEN | Financial Svcs | $23.40 | 8.0x(if norm) | ~0x(corp) | No moat | No buys | 3 Buy/4 Sell | Improving | 3 flags | LOW (div cut risk) |
Why #1: The rare combination of (a) cheapest forward P/E at 8.5x, (b) genuine insider buying (CFO at $86.54, Director at $77 with $770K), (c) 4-for-4 earnings beats with +43% adj EPS growth, (d) $10B buyback authorization (25% of market cap), (e) 17 consecutive quarters below 90% combined ratio, and (f) zero analyst sell ratings.
Valuation: Break-even growth rate on trailing EPS is just 2.7%. At 3% growth, Graham IV = $79 (4% MOS). At 5%, IV = $101 (25% MOS). Forward P/E of 8.5x means the market prices zero growth — far too pessimistic for a company returning 25% of market cap in buybacks.
Moat (Dorsey): Narrow. Intangible assets (specialty underwriting expertise, Lexington E&S platform) + efficient scale in global specialty lines. Not wide, but sufficient.
Downside (Klarman): Catastrophe loss season is the primary risk. A 2017-style cat year could push combined ratio above 95%, compressing EPS materially. Reserve deficiency from social inflation is the slow-burn structural risk. Worst case: $60-65 (-15-20%).
Schilit: 1 flag (minor). Clean accounting.
Lynch: Fast grower (earnings inflection phase). Correct — AIG is at a profitability inflection after years of turnaround.
Red flag check (shr-034): Multiple GREEN flags. Earnings improving, insiders buying, balance sheet improving, analysts constructive. This is the rare screen candidate where RED flags ARE flipping to GREEN.
Why #2: Best balance sheet in the entire screen (0.10x net debt/EBITDA), Del Webb 55+ brand provides defensible niche moat, 56% analyst buy ratings, 4 consecutive adjusted earnings beats, and the most reasonable gross margin trajectory among homebuilders (26.4% vs LEN's 8.9% collapse).
Valuation: Break-even growth rate is 2.2%. At 3% growth, IV = $148 (21% MOS). Forward P/E of 10.4x with essentially flat EPS expectations — low bar.
Moat: Narrow. Del Webb is the moat — dominant 55+ brand with community switching costs. Scale purchasing is secondary.
Downside: Tariff cost shock ($17.5-30K per home) is the near-term risk. Move-up buyer lock-in effect (existing owners won't sell 3% mortgages). Worst case soft landing: $80-95. Recession: $48-72.
Key catalyst: April 23 Q1 2026 earnings. Consensus EPS $1.85 is a low bar. Tariff cost guidance update will be pivotal.
Critical finding: The screen's negative MOS (IV $9.96) was a data error. GAAP EPS includes massive spin-off losses. Corrected adjusted trailing P/E is 12.3x, forward P/E is 17.9x. At forward EPS, break-even growth is 5% — DD is at fair value, not deeply undervalued.
Why still interesting: FilmTec (RO membranes) is a narrow-to-wide moat asset with genuine switching costs. 8 consecutive quarterly beats. 23/26 analysts at Buy. Post-spin balance sheet is clean.
Why not actionable now: Forward P/E of 17.9x is not Graham-cheap. The analyst bull case ($55.79 PT, +23%) is already priced for the water infrastructure thesis. Not a margin-of-safety play.
Valuation is cheap (12.7x trailing) but earnings are declining (-22% YoY). Bond-adjusted Graham formula only justifies the price at 3%+ growth, which requires a housing cycle recovery that hasn't started.
Key concern: Insiders sold at $182-183 at the highs. Zero open-market buys at $140, a 24% discount. Combined with rates at 6.6-6.8%, entry-level buyer affordability stress, and 2/4 quarterly misses, this is a "wait for earnings trough confirmation" situation.
Next catalyst: April 21 earnings. Consensus $2.15 EPS.
The ultra-contrarian play. Zero analyst buys (8 sells/strong sells), 13% short interest with 12.4 DTC, priced at 9.4x earnings — the market is pricing TROW for terminal decline. But: zero debt, $3.38B cash, 5.8% Dividend Aristocrat yield, 55% payout ratio (safe), and OHA alternatives pivot underway.
Moat erosion is real — passive flows are structural and permanent. But TROW at 9.4x is priced for zero growth, which implies the $5.20 dividend alone provides 5.8% return. With even 2% growth, Graham IV = $124 (27% MOS).
Risk: Double-levered to equity markets (beta 1.5 + AUM beta). A 30% S&P drawdown could send this to $55-60.
Deepest drawdown at -44% from 52w high. Two genuine insider buys near the low ($2.78M by Director, $2.16M by CenterWell President) — the strongest insider signal of any candidate per shr-002.
But the operational crisis is severe: Q4 MLR at 88.3% (dangerous), FCF collapsed 84%, new $1B debt issuance, management guided $9.00 EPS (vs consensus $15.29 — massive gap). The forward P/E is 19.8x on management's own guide, not cheap.
Binary catalyst: April 29 Q1 2026 earnings + CMS 2027 final rate rule (April/May). If MLR recovers toward 83-84% and Stars trajectory stabilizes, this is a 2-3 bagger from here. If crisis deepens, $100-120 is possible.
Cheap on every metric (P/FCF 7.5x, 5.15% yield, net cash) but Apple represents ~60% of revenue. Apple's multi-year effort to reduce SWKS content (qualifying Qualcomm RFFE) is the existential risk. Short interest at 14.5% and rising (+6.7% MoM) — informed bears adding.
If Apple content holds, this is a $70-90 stock. If Apple accelerates in-sourcing, forward EPS of $4.99 is fiction and the stock is $37-43. No insider buying signals no management conviction.
4 consecutive earnings misses. Gross margin collapsed from 15.6% to 8.9%. Hunterbrook short report on land-light margin destruction. 7 analyst sells vs 3 buys. Fresh 52-week low. Zero insider buying at -40% from highs.
Balance sheet is excellent but the Millrose transition has fundamentally changed the P&L structure. Not investable until margin stabilization is demonstrated (June 15 earnings at earliest).
3 Schilit flags (worst of all candidates). Dividend payout is 122% of GAAP EPS and 99% of SBC-adjusted FCF — zero cushion. FTSE All-World Index removal triggered forced selling. Western Asset DOJ criminal cleared but civil liability pending. Zero insider open-market buys.
The 54% MOS and 8.0x forward P/E only exist if EPS normalizes from $1.08 to $2.91 — a 169% jump that requires Western Asset stabilization + market recovery + fee rate hold. All three face headwinds.
| Ticker | Soft Bear | Hard Bear | Tail Risk |
|---|---|---|---|
| AIG | -15% | -30% | -50% (cat year) |
| PHM | -20% | -35% | -60% (recession) |
| DD | -15% | -25% | -40% (PFAS) |
| DHI | -18% | -43% | -79% (2008-style) |
| TROW | -20% | -40% | -65% (sustained bear) |
| HUM | -25% | -45% | -70% (MLR + Stars) |
| SWKS | -25% | -40% | -65% (Apple exits) |
| LEN | -20% | -40% | -70% (recession) |
| BEN | -20% | -50% | -60% (div cut) |
| Category | Tickers |
|---|---|
| Fast Grower (inflection) | AIG, HUM |
| Stalwart | PHM |
| Slow Grower | TROW, BEN |
| Cyclical | DHI, LEN |
| Post-Restructuring | DD |
| Ticker | RED→GREEN flips? | Deploy T1? |
|---|---|---|
| AIG | YES — earnings, insiders, capital return all GREEN | YES |
| PHM | Partial — earnings beats, but tariff risk unresolved | Wait for Apr 23 |
| DD | N/A — not deeply undervalued on corrected data | Not a Graham play |
| DHI | NO — earnings declining, no insiders buying | Wait |
| TROW | NO — secular headwinds, zero analyst buys | Wait |
| HUM | Partial — insider buying GREEN, but MLR/FCF RED | Wait for Apr 29 |
| SWKS | NO — Apple risk RED, shorts adding | Wait |
| LEN | NO — 4 misses, margin collapse, no catalyst | Wait |
| BEN | NO — dividend at risk, 3 Schilit flags | Avoid |